Per Hall

Per Hall

Professor, Senior
E-postadress: per.hall@ki.se
Telefon: +46852482421
Mobiltelefon: +46733960590
Besöksadress: Nobels väg 12a, 17165 Solna
Postadress: C8 Medicinsk epidemiologi och biostatistik, C8 MEB III Hall, 171 77 Stockholm

Om mig

  • Jag är professor vid Institutionen för medicinsk epidemiologi och biostatistik, för att läsa mer om mig och min forskning inom bröstcancer vänligen byt språk till engelska.

Utvalda publikationer

Artiklar

Alla övriga publikationer

  • Conference publication: EUROPEAN JOURNAL OF HUMAN GENETICS. 2025;33:450
    Zhang X; Eriksson M; Mavaddat N; Dennis J; Vachon CM; Hall P; Easton DF
  • Corrigendum: NATURE COMMUNICATIONS. 2025;16(1):8237
    Lawrenson K; Kar S; McCue K; Kuchenbaeker K; Michailidou K; Tyrer J; Beesley J; Ramus SJ; Li Q; Delgado MK; Lee JM; Aittomaki K; Andrulis IL; Anton-Culver H; Arndt V; Arun BK; Arver B; Bandera EV; Barile M; Barkardottir RB; Barrowdale D; Beckmann MW; Benitez J; Berchuck A; Bisogna M; Bjorge L; Blomqvist C; Blot W; Bogdanova N; Bojesen A; Bojesen SE; Bolla MK; Bonanni B; Borresen-Dale A-L; Brauch H; Brennan P; Brenner H; Bruinsma F; Brunet J; Buhari SA; Burwinkel B; Butzow R; Buys SS; Cai Q; Caldes T; Campbell I; Cannioto R; Chang-Claude J; Chiquette J; Choi J-Y; Claes KBM; Collonge-Rame M-A; Damette A; Barouk-Simonet E; Bonnet F; Bubien V; Sevenet N; Longy M; Vaur D; Berthet P; Castera L; Ferrer SF; Bignon Y-J; Uhrhammer N; Coron F; Faivre L; Baurand A; Jacquot C; Bertolone G; Lizard S; Leroux D; Dreyfus H; Rebischung C; Peysselon M; Peyrat J-P; Fournier J; Revillion F; Adenis C; Venat-Bouvet L; Leone M; Boutry-Kryza N; Calender A; Giraud S; Verny-Pierre C; Lasset C; Bonadona V; Barjhoux L; Sobol H; Bourdon V; Noguchi T; Remenieras A; Coupier I; Pujol P; Sokolowska J; Bronner M; Delnatte C; Bezieau S; Mari V; Gauthier-Villars M; Buecher B; Rouleau E; Golmard L; Moncoutier V; Belotti M; de Pauw A; Elan C; Fourme E; Birot A-M; Saule C; Laurent M; Houdayer C; Lesueur F; Mebirouk N; Coulet F; Colas C; Soubrier F; Warcoin M; Prieur F; Lebrun M; Kientz C; Muller D; Fricker J-P; Toulas C; Guimbaud R; Gladieff L; Feillel V; Mortemousque I; Bressac-de-Paillerets B; Caron O; Guillaud-Bataille M; Cook LS; Cox A; Cramer DW; Cross SS; Cybulski C; Czene K; Daly MB; Damiola F; Dansonka-Mieszkowska A; Darabi H; Dennis J; Devilee P; Diez O; Doherty JA; Domchek SM; Dorfling CM; Dork T; Dumont M; Ehrencrona H; Ejlertsen B; Ellis S; Gregory H; Miedzybrodzka Z; Morrison PJ; Donaldson A; Rogers MT; Kennedy MJ; Porteous ME; Brady A; Barwell J; Foo C; Lalloo F; Side LE; Eason J; Henderson A; Walker L; Cook J; Snape K; Murray A; Mccann E; Engel C; Lee E; Evans DG; Fasching PA; Feliubadalo L; Figueroa J; Flesch-Janys D; Fletcher O; Flyger H; Foretova L; Fostira F; Foulkes WD; Fridley BL; Friedman E; Frost D; Gambino G; Ganz PA; Garber J; Garcia-Closas M; Gentry-Maharaj A; Ghoussaini M; Giles GG; Glasspool R; Godwin AK; Goldberg MS; Goldgar DE; Gonzalez-Neira A; Goode EL; Goodman MT; Greene MH; Gronwald J; Guenel P; Haiman CA; Hall P; Hallberg E; Hamann U; Hansen TVO; Harrington PA; Hartman M; Hassan N; Healey S; Rookus MA; van Leeuwen FE; van der Kolk LE; Schmidt MK; Russell NS; de Lange JL; Wijnands R; Collee JM; Hooning MJ; Seynaeve C; van Deurzen CHM; Obdeijn IM; van Asperen CJ; Tollenaar RAEM; van Cronenburg TCTEF; Kets CM; Ausems MGEM; van der Pol CC; van Os TAM; Waisfisz Q; Meijers-Heijboer HEJ; Gomez-Garcia EB; Oosterwijk JC; Mourits MJ; de Bock GH; Vasen HF; Siesling S; Verloop J; Overbeek LIH; Heitz F; Herzog J; Hogdall E; Hogdall CK; Hogervorst FBL; Hollestelle A; Hopper JL; Hulick PJ; Huzarski T; Imyanitov EN; Fox S; Kirk J; Lindeman G; Price M; Bowtell D; Defazio A; Webb P; Isaacs C; Ito H; Jakubowska A; Janavicius R; Jensen A; John EM; Johnson N; Kabisch M; Kang D; Kapuscinski M; Karlan BY; Khan S; Kiemeney LA; Kjaer SK; Knight JA; Konstantopoulou I; Kosma V-M; Kristensen V; Kupryjanczyk J; Kwong A; de la Hoya M; Laitman Y; Lambrechts D; Le N; De Leeneer K; Lester J; Levine DA; Li J; Lindblom A; Long J; Lophatananon A; Loud JT; Lu K; Lubinski J; Mannermaa A; Manoukian S; Le Marchand L; Margolin S; Marme F; Massuger LFAG; Matsuo K; Mazoyer S; Mcguffog L; McLean C; McNeish I; Meindl A; Menon U; Mensenkamp AR; Milne RL; Montagna M; Moysich KB; Muir K; Mulligan AM; Nathanson KL; Ness RB; Neuhausen SL; Nevanlinna H; Nord S; Nussbaum RL; Odunsi K; Offit K; Olah E; Olopade OI; Olson JE; Olswold C; O'Malley D; Orlow I; Orr N; Osorio A; Park SK; Pearce CL; Pejovic T; Peterlongo P; Pfeiler G; Phelan CM; Poole EM; Pylkas K; Radice P; Rantala J; Rashid MU; Rennert G; Rhenius V; Rhiem K; Risch HA; Rodriguez G; Rossing MA; Rudolph A; Salvesen HB; Sangrajrang S; Sawyer EJ; Schildkraut JM; Schmidt MK; Schmutzler RK; Sellers TA; Seynaeve C; Shah M; Shen C-Y; Shu X-O; Sieh W; Singer CF; Sinilnikova OM; Slager S; Song H; Soucy P; Southey MC; Stenmark-Askmalm M; Stoppa-Lyonnet D; Sutter C; Swerdlow A; Tchatchou S; Teixeira MR; Teo SH; Terry KL; Terry MB; Thomassen M; Tibiletti MG; Tihomirova L; Tognazzo S; Toland AE; Tomlinson I; Torres D; Truong T; Tseng C-C; Tung N; Tworoger SS; Vachon C; van den Ouweland AMW; van Doorn HC; van Rensburg EJ; Van't Veer LJ; Vanderstichele A; Vergote I; Vijai J; Wang Q; Wang-Gohrke S; Weitzel JN; Wentzensen N; Whittemore AS; Wildiers H; Winqvist R; Wu AH; Yannoukakos D; Yoon S-Y; Yu J-C; Zheng W; Zheng Y; Khanna KK; Simard J; Monteiro AN; French JD; Couch FJ; Freedman ML; Easton DF; Dunning AM; Pharoah PD; Edwards SL; Chenevix-Trench G; Antoniou AC; Gayther SA
  • Letter: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025;117(9):1950
    Hammarstrom M; Hall P
  • Conference publication: BREAST CANCER RESEARCH AND TREATMENT. 2025;211(1):S26-S27
    Eriksson M; Czene K; Conant EC; Hall P
  • Preprint: MEDRXIV. 2025
    Zhang X; Eriksson M; Mavaddat N; Dennis J; Astley SM; Gabrielson M; Giles GG; Hart SN; Hunter DJ; Le Marchand L; Lush M; Michailidou K; Scott CG; Wang Q; Howell SJ; Naven M; Antoniou AC; Aronson KJ; Bolla MK; Castelao JE; Couch FJ; Czene K; Dunning AM; Evans DG; Gago-Dominguez M; García-Closas M; Haiman CA; Milne RL; Pharoah PDP; Southey MC; Stone J; Murphy RA; de Gonzalez AB; Vachon CM; Hall P; Easton DF
  • Preprint: MEDRXIV. 2025;MEDRXIV
    Ho PJ; Loo CKY; Goh MH; Abubakar M; Ahearn TU; Andrulis IL; Antonenkova NN; Aronson KJ; Augustinsson A; Behrens S; Bodelon C; Bogdanova NV; Bolla MK; Brantley K; Brenner H; Byers H; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Choi J-Y; Colonna SV; Czene K; Daly MB; Derouane F; Dörk T; Eliassen AH; Engel C; Eriksson M; Evans DG; Fletcher O; Fritschi L; Gago-Dominguez M; Genkinger JM; Geurts-Giele WRR; Glendon G; Hall P; Hamann U; Ho CYS; Ho W-K; Hooning MJ; Hoppe R; Howell A; Humphreys K; ABCTB Investigators; kConFab Investigators; SGBCC Investigators; MyBrCa Investigators; Ito H; Iwasaki M; Jakubowska A; Jernström H; John EM; Johnson N; Kang D; Kim S-W; Kitahara CM; Ko Y-D; Kraft P; Kwong A; Lambrechts D; Larsson S; Li S; Lindblom A; Linet M; Lissowska J; Lophatananon A; MacInnis RJ; Mannermaa A; Manoukian S; Margolin S; Matsuo K; Michailidou K; Milne RL; Taib NAM; Muir K; Murphy RA; Newman WG; O'Brien KM; Obi N; Olopade OI; Panayiotidis MI; Park SK; Park-Simon T-W; Patel AV; Peterlongo P; Plaseska-Karanfilska D; Pylkäs K; Rashid MU; Rennert G; Rodriguez J; Saloustros E; Sandler DP; Sawyer EJ; Scott CG; Shahi S; Shu X-O; Shulman K; Simard J; Southey MC; Stone J; Taylor JA; Teo S-H; Teras LR; Terry MB; Torres D; Vachon CM; Van Houdt M; Verhoeven J; Weinberg CR; Wolk A; Yamaji T; Yip CH; Zheng W; Hartman M; Li J
  • Preprint: MEDRXIV. 2025
    Ficorella L; Yang X; Mavaddat N; Carver T; Hassan H; Dennis J; Tyrer J; Ho W-K; Teo S-H; Hartman M; Li J; Eriksson M; Czene K; Hall P; Rahman T; Bacon A; Hardy S; Stokes AE; Donoso FS; Archer S; Simard J; Pharoah PDP; Usher-Smith JA; Tischkowitz M; Easton DF; Antoniou AC
  • Preprint: MEDRXIV. 2025
    Ficorella L; Eriksson M; Czene K; Leslie G; Yang X; Carver T; Stokes AE; Easton DF; Hall P; Antoniou AC
  • Corrigendum: NATURE GENETICS. 2024;56(8):1763-1764
    Kentistou KA; Kaisinger LR; Stankovic S; Vaudel M; de Oliveira EM; Messina A; Walters RG; Liu X; Busch AS; Helgason H; Thompson DJ; Santoni F; Petricek KM; Zouaghi Y; Huang-Doran I; Gudbjartsson DF; Bratland E; Lin K; Gardner EJ; Zhao Y; Jia RY; Terao C; Riggan MJ; Bolla MK; Yazdanpanah M; Yazdanpanah N; Bradfield JP; Broer L; Campbell A; Chasman DI; Cousminer DL; Franceschini N; Franke LH; Girotto G; He C; Jarvelin M-R; Joshi PK; Kamatani Y; Karlsson R; Luan J; Lunetta KL; Maegi R; Mangino M; Medland SE; Meisinger C; Noordam R; Nutile T; Concas MP; Polasek O; Porcu E; Ring SM; Sala C; Smith AV; Tanaka T; van der Most PJ; Vitart V; Wang CA; Willemsen G; Zygmunt M; Ahearn TU; Andrulis IL; Anton-Culver H; Antoniou AC; Auer PL; Barnes CLK; Beckmann MW; de Gonzalez AB; Bogdanova NV; Bojesen SE; Brenner H; Buring JE; Canzian F; Chang-Claude J; Couch FJ; Cox A; Crisponi L; Czene K; Daly MB; Demerath EW; Dennis J; Devilee P; De Vivo I; Dork T; Dunning AM; Dwek M; Eriksson JG; Fasching PA; Fernandez-Rhodes L; Ferreli L; Fletcher O; Gago-Dominguez M; Garcia-Closas M; Garcia-Saenz JA; Gonzalez-Neira A; Grallert H; Guenel P; Haiman CA; Hall P; Hamann U; Hakonarson H; Hart RJ; Hickey M; Hooning MJ; Hoppe R; Hopper JL; Hottenga J-J; Hu FB; Huebner H; Hunter DJ; Jernstrom H; John EM; Karasik D; Khusnutdinova EK; Kristensen VN; Lacey JV; Lambrechts D; Launer LJ; Lind PA; Lindblom A; Magnusson PKE; Mannermaa A; McCarthy MI; Meitinger T; Menni C; Michailidou K; Millwood IY; Milne RL; Montgomery GW; Nevanlinna H; Nolte IM; Nyholt DR; Obi N; O'Brien KM; Offit K; Oldehinkel AJ; Ostrowski SR; Palotie A; Pedersen OB; Peters A; Pianigiani G; Plaseska-Karanfilska D; Pouta A; Pozarickij A; Radice P; Rennert G; Rosendaal FR; Ruggiero D; Saloustros E; Sandler DP; Schipf S; Schmidt CO; Schmidt MK; Small K; Spedicati B; Stampfer M; Stone J; Tamimi RM; Teras LR; Tikkanen E; Turman C; Vachon CM; Wang Q; Winqvist R; Wolk A; Zemel BS; Zheng W; van Dijk KW; Alizadeh BZ; Bandinelli S; Boerwinkle E; Boomsma DI; Ciullo M; Chenevix-Trench G; Cucca F; Esko T; Gieger C; Grant SFA; Gudnason V; Hayward C; Kolcic I; Kraft P; Lawlor DA; Martin NG; Nohr EA; Pedersen NL; Pennell CE; Ridker PM; Robino A; Snieder H; Sovio U; Spector TD; Stockl D; Sudlow C; Timpson NJ; Toniolo D; Uitterlinden A; Ulivi S; Volzke H; Wareham NJ; Widen E; Wilson JF; Pharoah PDP; Li L; Easton DF; Njolstad PR; Sulem P; Murabito JM; Murray A; Manousaki D; Juul A; Erikstrup C; Stefansson K; Horikoshi M; Chen Z; Farooqi IS; Pitteloud N; Johansson S; Day FR; Perry JRB; Ong KK
  • Preprint: MEDRXIV. 2024
    Wilcox N; Tyrer JP; Dorling L; Dennis J; Naven M; Abubakar M; Ahearn TU; Andrulis IL; Antoniou AC; Bogdanova NV; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Chang-Claude J; Czene K; Dörk T; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gardner EJ; González-Neira A; Guénel P; Hahnen E; Hall P; Hartman M; Hooning MJ; Jakubowska A; Khusnutdinova EK; Kristensen VN; Li J; Lindblom A; Lophatananon A; Mannermaa A; Manoukian S; Milne RL; Nuñez-Torres R; Obi N; Panayiotidis MI; Park SK; Perry JRB; Rashid MU; Saloustros E; Sawyer EJ; Schmidt MK; Southey MC; Spurdle AB; Torres D; Wang Q; Simard J; Teo SH; Dunning AM; Devilee P; Easton DF
  • Conference publication: CANCER SCIENCE. 2024;115:733
    Ong J; Seviiri M; Gharahkhani P; Law MH; Webb PM; Neale RE; Whiteman D; Dusingize JC; Trench GC; Derks EM; Bojesen SE; Hall P; Kendall B; Macgregor S
  • Preprint: RESEARCH SQUARE. 2024
    Tapia J; Gabrielson M; Hammarström M; Wengström Y; Bergqvist J; Tuuliainen A; Eriksson M; Czene K; Hall P; Bäcklund M
  • Preprint: MEDRXIV. 2024;MEDRXIV
    Yiangou K; Mavaddat N; Dennis J; Zanti M; Wang Q; Bolla MK; Abubakar M; Ahearn TU; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Augustinsson A; Baten A; Behrens S; Bermisheva M; de Gonzalez AB; Białkowska K; Boddicker N; Bodelon C; Bogdanova NV; Bojesen SE; Brantley KD; Brauch H; Brenner H; Camp NJ; Canzian F; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; Chung WK; NBCS Collaborators; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; Dunning AM; Eccles DM; Eliassen AH; Engel C; Eriksson M; Evans DG; Fasching PA; Fletcher O; Flyger H; Fritschi L; Gago-Dominguez M; Gentry-Maharaj A; González-Neira A; Guénel P; Hahnen E; Haiman CA; Hamann U; Hartikainen JM; Ho V; Hodge J; Hollestelle A; Honisch E; Hooning MJ; Hoppe R; Hopper JL; Howell S; Howell A; ABCTB Investigators; kConFab Investigators; Jakovchevska S; Jakubowska A; Jernström H; Johnson N; Kaaks R; Khusnutdinova EK; Kitahara CM; Koutros S; Kristensen VN; Lacey JV; Lambrechts D; Lejbkowicz F; Lindblom A; Lush M; Mannermaa A; Mavroudis D; Menon U; Murphy RA; Nevanlinna H; Obi N; Offit K; Park-Simon T-W; Patel AV; Peng C; Peterlongo P; Pita G; Plaseska-Karanfilska D; Pylkäs K; Radice P; Rashid MU; Rennert G; Roberts E; Rodriguez J; Romero A; Rosenberg EH; Saloustros E; Sandler DP; Sawyer EJ; Schmutzler RK; Scott CG; Shu X-O; Southey MC; Stone J; Taylor JA; Teras LR; van de Beek I; Willett W; Winqvist R; Zheng W; Vachon CM; Schmidt MK; Hall P; MacInnis RJ; Milne RL; Pharoah PDP; Simard J; Antoniou AC; Easton DF; Michailidou K
  • Preprint: MEDRXIV. 2023;MEDRXIV
    Kentistou KA; Kaisinger LR; Stankovic S; Vaudel M; de Oliveira EM; Messina A; Walters RG; Liu X; Busch AS; Helgason H; Thompson DJ; Santon F; Petricek KM; Zouaghi Y; Huang-Doran I; Gudbjartsson DF; Bratland E; Lin K; Gardner EJ; Zhao Y; Jia R; Terao C; Riggan M; Bolla MK; Yazdanpanah M; Yazdanpanah N; Bradfield JP; Broer L; Campbell A; Chasman DI; Cousminer DL; Franceschini N; Franke LH; Girotto G; He C; Järvelin M-R; Joshi PK; Kamatani Y; Karlsson R; Luan J; Lunetta KL; Mägi R; Mangino M; Medland SE; Meisinger C; Noordam R; Nutile T; Concas MP; Polašek O; Porcu E; Ring SM; Sala C; Smith AV; Tanaka T; van der Most PJ; Vitart V; Wang CA; Willemsen G; Zygmunt M; Ahearn TU; Andrulis IL; Anton-Culver H; Antoniou AC; Auer PL; Barnes CL; Beckmann MW; Berrington A; Bogdanova NV; Bojesen SE; Brenner H; Buring JE; Canzian F; Chang-Claude J; Couch FJ; Cox A; Crisponi L; Czene K; Daly MB; Demerath EW; Dennis J; Devilee P; Vivo ID; Dörk T; Dunning AM; Dwek M; Eriksson JG; Fasching PA; Fernandez-Rhodes L; Ferreli L; Fletcher O; Gago-Dominguez M; García-Closas M; García-Sáenz JA; González-Neira A; Grallert H; Guénel P; Haiman CA; Hall P; Hamann U; Hakonarson H; Hart RJ; Hickey M; Hooning MJ; Hoppe R; Hopper JL; Hottenga J-J; Hu FB; Hübner H; Hunter DJ; ABCTB Investigators; Jernström H; John EM; Karasik D; Khusnutdinova EK; Kristensen VN; Lacey JV; Lambrechts D; Launer LJ; Lind PA; Lindblom A; Magnusson PK; Mannermaa A; McCarthy MI; Meitinger T; Menni C; Michailidou K; Millwood IY; Milne RL; Montgomery GW; Nevanlinna H; Nolte IM; Nyholt DR; Obi N; O'Brien KM; Offit K; Oldehinkel AJ; Ostrowski SR; Palotie A; Pedersen OB; Peters A; Pianigiani G; Plaseska-Karanfilska D; Pouta A; Pozarickij A; Radice P; Rennert G; Rosendaal FR; Ruggiero D; Saloustros E; Sandler DP; Schipf S; Schmidt CO; Schmidt MK; Small K; Spedicati B; Stampfer M; Stone J; Tamimi RM; Teras LR; Tikkanen E; Turman C; Vachon CM; Wang Q; Winqvist R; Wolk A; Zemel BS; Zheng W; van Dijk KW; Alizadeh BZ; Bandinelli S; Boerwinkle E; Boomsma DI; Ciullo M; Chenevix-Trench G; Cucca F; Esko T; Gieger C; Grant SF; Gudnason V; Hayward C; Kolčić I; Kraft P; Lawlor DA; Martin NG; Nøhr EA; Pedersen NL; Pennell CE; Ridker PM; Robino A; Snieder H; Sovio U; Spector TD; Stöckl D; Sudlow C; Timpson NJ; Toniolo D; Uitterlinden A; Ulivi S; Völzke H; Wareham NJ; Widen E; Wilson JF; Lifelines Cohort Study; Danish Blood Donor study; Ovarian Cancer Association Consortium; Breast Cancer Association Consortium; Biobank Japan Project; China Kadoorie Biobank Collaborative Group; Pharoah PD; Li L; Easton DF; Njølstad P; Sulem P; Murabito JM; Murray A; Manousaki D; Juul A; Erikstrup C; Stefansson K; Horikoshi M; Chen Z; Farooqi IS; Pitteloud N; Johansson S; Day FR; Perry JR; Ong KK
  • Preprint: RESEARCH SQUARE. 2023
    Malarstig A; Grassman F; Dahl L; Dimitriou M; Mcleod D; Gabrielson M; Smith-Byrne K; Thomas C; Huang T-H; Forsberg S; Eriksson P; Ulfstedt M; Johansson M; Sokolov A; Schioth H; Hall P; Schwenk J; Czene K; Hedman A
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Holowko N; Eriksson M; Kuja-Halkola R; Azam S; He W; Hall P; Czene K
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Holowko N; Eriksson M; Kuja-Halkola R; Azam S; He W; Hall P; Czene K
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Holowko N; Eriksson M; Kuja-Halkola R; Azam S; He W; Hall P; Czene K
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Holowko N; Eriksson M; Kuja-Halkola R; Azam S; He W; Hall P; Czene K
  • Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
    Holowko N; Eriksson M; Kuja-Halkola R; Azam S; He W; Hall P; Czene K
  • Visa fler

Forskningsbidrag

  • Swedish Research Council
    1 januari 2026 - 31 december 2029
    Mammography screening reduces breast cancer mortality, yet interval cancers - tumors diagnosed between screening rounds - constitute a major limitation, often presenting with aggressive phenotypes and poor prognoses. This project aims to identify epidemiological, biological, and imaging determinants of interval breast cancer to enhance risk stratification and screening efficacy. We will investigate the association between inherited genetic susceptibility, circulating biomarkers, mammographic features, and hormonal/lifestyle factors with interval cancer risk. Additionally, we will assess prognostic differences between interval and screen-detected cancers and develop an improved risk model for tailored screening strategies.The study is based on extensive Swedish population-based cohorts with linked screening, clinical, molecular, and epidemiological data. We will employ next-generation sequencing to analyze rare genetic variants, assess blood-based biomarkers for early risk detection, and apply AI-driven mammographic analysis to identify imaging features associated with interval cancers. Statistical approaches, including Cox proportional hazards models and machine learning-based risk prediction, will be utilized.Our research will provide new insights into the etiology of interval cancers and their missed detection in screening. The results will inform risk-adaptive screening strategies, ultimately improving early cancer detection and reducing mortality.
  • Swedish Research Council
    1 januari 2024 - 31 december 2027
    The aim of breast cancer screening is early detection of breast cancers. Mammography screening is so far the only proven method that reduces mortality from breast cancer. Mortality from breast cancer is 20-40% lower in screened women compared to non-screened women.Among women attending the Swedish Mammography Screening Program approximately every third breast cancers is diagnosed with breast cancer in the interval between two screens, a so-called interval cancer. The interval cancers could be either masked by high mammographic density, missed at the previous screening round or fast growing and actually developing in between two screening rounds. Interval cancers are more common in women with dense breasts and are considered more aggressive than screen detected cancers.The risk of breast cancer and the possibility to detect a cancer differs profoundly between women. Women with mammographically dense breasts have an increased risk of breast cancer and the possibility to diagnose a prevalent breast is reduced due to “masking”. Women with dense breast are more likely to be diagnosed with an interval cancer then women with non-dense breasts.The aim of SMART, The Swedish Mammography Risk stratified Trial, is to test the effectiveness of individualised breast cancer screening. In short - does an individualised screening program identify cancers at an earlier, curable stage, compared to the current one-fits-all approach?
  • Swedish Cancer Society
    1 januari 2024
    The risk of breast cancer and the possibility of detecting a cancer during a mammography examination differ. Some women have a very high risk of breast cancer and difficult-to-examine, "dense", breasts. Other women have a low risk of breast cancer. Despite major differences, women are examined in the same way, regardless of risk and density. All women between the ages of 40-74 are called to screening every two years. Today it is possible to assess the risk of developing breast cancer. With the help of detailed, artificial intelligence-supported examination of the mammogram images, it is possible to identify women at high risk of developing cancer and who have difficult-to-examine breasts. In SMART, we investigate whether individualized screening is more effective than the current age-based screening. Women who have been called for mammography screening at Södersjukhuset are asked. Those who accept to be part of SMART are drawn to either be screened in the usual way or to have their risk measured and have the screening individualized. Women who are judged to have a high risk are offered a contrast-enhanced mammogram within a month or so after the mammogram examination and another mammogram examination after 12 months. We estimate that every fifth woman has such a high risk of breast cancer that she will be offered extra examinations. The primary objectives are to investigate whether individualized screening detects cancers at an earlier, curable, stage and whether fewer cancers are missed by screening. We will also investigate the differences in how many women are recalled and biopsied in the two groups. In addition, the perceived anxiety in connection with screening is compared to the anxiety of a future cancer. We also study side effects of contrast-enhanced mammography and the costs associated with individualized screening.
  • Swedish Cancer Society
    1 januari 2021
    Every hour a woman is diagnosed with breast cancer in Sweden, and breast cancer is the most common cause of death for middle-aged women. Mammography screening reduces mortality from breast cancer by detecting the tumors in good time. Women with very dense breasts are difficult to examine and a mammogram examination is not effective. A contrast-enhanced mammogram may be an option. The number of women diagnosed has been increasing for many years. There are medications that halve the risk of developing breast cancer. We want to test whether a tailored screening and preventive measures reduce incidence and mortality from breast cancer. During a 2-year period, we want to invite 80,000 women to SMART – Stockholm Mammography Risk Trial. In SMART, we want to offer women to have their risk of breast cancer measured. Those women who have a low or average risk continue to be screened just as usual, every two years. Women at increased risk and/or dense breasts are examined with contrast-enhanced mammography and those women at very high risk are offered preventive medication. By assessing the risk of breast cancer and tailoring the screening and preventive treatment, more breast cancers will be detected at an earlier stage and some cancers will never even be diagnosed. Breast cancer is a very serious disease that affects patients, relatives and society. Sweden has always been far ahead in the treatment of breast cancer. There is no reason why we should not continue to drive development in the right direction.
  • Swedish Research Council
    1 januari 2020 - 31 december 2023
  • Individualiserad prevention och screening av bröstcancer
    Swedish Cancer Society
    1 januari 2018
    Every year, just over 9,000 cases of breast cancer are registered in Sweden. This means that more than one woman per hour becomes ill in the disease. Sweden may have the world's best screening program for breast cancer, which is one of the reasons why the mortality rate in the disease falls. The goal of the mammography screening is to detect the tumors early when bone is still possible. The goal of mammography screening is not to reduce the incidence of breast cancer. More and more women are suffering from breast cancer in Sweden and the rest of the world, but unfortunately not much is done to prevent breast cancer. Our vision is that all women who are invited to mammography screening should be asked if they want their individual risk measured. Women who accept this offer will receive a tailor-made screening program. Women with very low risk of breast cancer will be offered mammography screening at longer intervals. For women with normal risk and density, there is no need to change the current screening routines. Women at high risk for breast cancer will be offered additional examinations and preventative treatment. For women with very high risk, any genetic investigations will be carried out. The goal of our project is to detect cancer in the past and further improve survival and to prevent cancer in women at high risk for breast cancer. Sweden has one of the best mammography screening programs in the world, the researchers have extensive experience in carrying out this type of study, the staff is well-trained and which means that we in Sweden have all the prerequisites to take the next step in the development of breast cancer screening - the individual-based prevention and screening of breast cancer.
  • Swedish Research Council
    1 januari 2018 - 31 december 2021
  • Individualiserad prevention och screening av bröstcancer
    Swedish Cancer Society
    1 januari 2017
    Every year, just over 9,000 cases of breast cancer are registered in Sweden. This means that more than one woman per hour becomes ill in the disease. Sweden may have the world's best screening program for breast cancer, which is one of the reasons why the mortality rate in the disease falls. The goal of the mammography screening is to detect the tumors early when bone is still possible. The goal of mammography screening is not to reduce the incidence of breast cancer. More and more women are suffering from breast cancer in Sweden and the rest of the world, but unfortunately not much is done to prevent breast cancer. Our vision is that all women who are invited to mammography screening should be asked if they want their individual risk measured. Women who accept this offer will receive a tailor-made screening program. Women with very low risk of breast cancer will be offered mammography screening at longer intervals. For women with normal risk and density, there is no need to change the current screening routines. Women at high risk for breast cancer will be offered additional examinations and preventative treatment. For women with very high risk, any genetic investigations will be carried out. The goal of our project is to detect cancer in the past and further improve survival and to prevent cancer in women at high risk for breast cancer. Sweden has one of the best mammography screening programs in the world, the researchers have extensive experience in carrying out this type of study, the staff is well-trained and which means that we in Sweden have all the prerequisites to take the next step in the development of breast cancer screening - the individual-based prevention and screening of breast cancer.
  • Swedish Research Council for Health Working Life and Welfare
    1 januari 2017 - 31 december 2019
  • Genetic determinants of breast cancer
    Swedish Cancer Society
    1 januari 2016
    In Sweden, more than 8,000 women suffer from breast cancer every year. Put differently, a woman is affected by breast cancer in the hour. Very little is done to reduce the number of women diagnosed with breast cancer. If you compare with how much is done to reduce the incidence of cardiovascular diseases, eg Medicines to reduce blood pressure and high cholesterol levels are made virtually nothing to reduce the risk of breast cancer. A first step in all preventive activities is to identify the individuals who will suffer from a disease. In this project, we want to identify genetic changes that affect the risk of suffering from breast cancer. In 2013, we identified approximately 90 genetic changes that affect the risk of breast cancer. In collaboration with a large international breast cancer consortium, we have also discovered that there are probably at least 1000 additional changes that affect the risk of breast cancer. We want to map these. We also understand how these changes affect the risk of breast cancer. What Genetic Mechanisms Lead to Cancer? Finally, we want to use the discoveries to identify those women who will suffer from breast cancer. Knowing which factors give rise to a disease means that the underlying mechanism can be identified. Once the mechanism has been identified, effective drugs can be produced. Although one does not know the mechanism, the information on which factors affect the disease is important, as they can be used to identify people who will develop the disease. This means that preventive measures can be implemented effectively. In this project, we want to find genetic risk factors, understand the mechanisms and identify women at high risk of developing breast cancer.
  • Swedish Research Council
    1 januari 2016 - 31 december 2019
  • Genetic determinants of breast cancer
    Swedish Cancer Society
    1 januari 2015
    In Sweden, more than 8,000 women suffer from breast cancer every year. Put differently, a woman is affected by breast cancer in the hour. Very little is done to reduce the number of women diagnosed with breast cancer. If you compare with how much is done to reduce the incidence of cardiovascular diseases, eg Medicines to reduce blood pressure and high cholesterol levels are made virtually nothing to reduce the risk of breast cancer. A first step in all preventive activities is to identify the individuals who will suffer from a disease. In this project, we want to identify genetic changes that affect the risk of suffering from breast cancer. In 2013, we identified approximately 90 genetic changes that affect the risk of breast cancer. In collaboration with a large international breast cancer consortium, we have also discovered that there are probably at least 1000 additional changes that affect the risk of breast cancer. We want to map these. We also understand how these changes affect the risk of breast cancer. What Genetic Mechanisms Lead to Cancer? Finally, we want to use the discoveries to identify those women who will suffer from breast cancer. Knowing which factors give rise to a disease means that the underlying mechanism can be identified. Once the mechanism has been identified, effective drugs can be produced. Although one does not know the mechanism, the information on which factors affect the disease is important, as they can be used to identify people who will develop the disease. This means that preventive measures can be implemented effectively. In this project, we want to find genetic risk factors, understand the mechanisms and identify women at high risk of developing breast cancer.
  • Swedish Research Council
    1 januari 2015 - 31 december 2018
  • Genetic determinants of breast cancer
    Swedish Cancer Society
    1 januari 2014
    In Sweden, more than 8,000 women suffer from breast cancer every year. Put differently, a woman is affected by breast cancer in the hour. Very little is done to reduce the number of women diagnosed with breast cancer. If you compare with how much is done to reduce the incidence of cardiovascular diseases, eg Medicines to reduce blood pressure and high cholesterol levels are made virtually nothing to reduce the risk of breast cancer. A first step in all preventive activities is to identify the individuals who will suffer from a disease. In this project, we want to identify genetic changes that affect the risk of suffering from breast cancer. In 2013, we identified approximately 90 genetic changes that affect the risk of breast cancer. In collaboration with a large international breast cancer consortium, we have also discovered that there are probably at least 1000 additional changes that affect the risk of breast cancer. We want to map these. We also understand how these changes affect the risk of breast cancer. What Genetic Mechanisms Lead to Cancer? Finally, we want to use the discoveries to identify those women who will suffer from breast cancer. Knowing which factors give rise to a disease means that the underlying mechanism can be identified. Once the mechanism has been identified, effective drugs can be produced. Although one does not know the mechanism, the information on which factors affect the disease is important, as they can be used to identify people who will develop the disease. This means that preventive measures can be implemented effectively. In this project, we want to find genetic risk factors, understand the mechanisms and identify women at high risk of developing breast cancer.
  • Swedish Research Council
    1 januari 2014 - 31 december 2017
  • Swedish Research Council
    1 januari 2014 - 31 december 2018
  • Swedish Research Council
    1 januari 2012 - 31 december 2014
  • Swedish Research Council
    1 januari 2012 - 31 december 2015
  • Vetenskapsrådet
    1 januari 2012 - 31 december 2014
  • Visa fler

Anställningar

  • Professor, Senior, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2025-2026
  • Professor/Överläkare, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2017-2024
  • Professor, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2004-2017

Handledning

  • Handledning till doktorsexamen

    • Johanna Holm, Aggressive breast cancer: epidemiological studies addressing disease heterogeneity, 2023
    • Roxanna Hellgren, Beyond mammography: an evaluation of complementary modalities in breast imaging, 2023
    • Rickard Strandberg, Breast cancer natural history models and risk prediction in mammography screening cohorts, 2022
    • Kejia Hu, Psychological distress and breast cancer: a bidirectional link, 2022
    • Mattias Hammarström, Investigating the outcome of low and standard dose tamoxifen in healthy women, 2021-
    • Mikael Eriksson, Risk assessment and prevention of breast cancer, 2021
    • Shadi Azam, Determinants and influence of mammographic features on breast cancer risk, 2020
    • Emilio Ugalde Morales, Molecular epidemiology studies on risk factors for breast cancer and disease aggressiveness, 2020
    • Haomin Yang, Panorama of diseases associated with breast cancer, 2018
    • Linda Abrahamsson, Statistical models of breast cancer tumour progression for mammography screening data, 2018
    • Fredrik Strand, Determinants of interval cancer and tumor size among breast cancer screening participants, 2016
    • Tang Trinh, Determinants of breast cancer risk: focusing on mammographic density, 2016
    • Edoardo Colzani, Health outcomes of women with breast cancer, 2014
    • Hatef Darabi, Genetic association and risk prediction of breast cancer from an epidemiological and biostatistical perspective, 2012
    • Maria Sandberg (Schelin), Contralateral Breast Cancer - Risk and Prognosis, 2012
    • Louise Eriksson, Mammographic density and breast cancer phenotypes, 2012
    • Jingmei Li, Genetic determinants of breast cancer risk, 2011
    • Chantal Mascarenhas (Orgéas), Endogenous and exogenous hormonal factors in female cancers – studies of risk and prognosis, 2009
    • Mikael Hartman, Risk and prognosis of breast cancer among women at high risk of the disease, 2007
    • Kristjana Einarsdottir, Genetic determinants of postmenopausal breast and endometrial cancer, 2007
    • Michaela Prochazka, The risk of second primary lung carcinoma in breast cancer patients, 2006
    • Catharina Ihre Lundgren, Incidence and prognosis of differentiated thyroid cancer in Sweden, 2006
    • Lena Rosenberg, Hormone-related factors and breast cancer: studies of risk and prognosis, 2006
    • Ullakarin Nyberg, Mortality and cancer incidence following cerebral angiography with thorotrast, 2002
    • Kjell Bergfeldt, 2001

Nyheter från KI

Kalenderhändelser från KI